(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 163.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Nuvation Bio's revenue in 2026 is $26,748,000.On average, 12 Wall Street analysts forecast NUVB's revenue for 2026 to be $56,162,972,994, with the lowest NUVB revenue forecast at $35,760,955,396, and the highest NUVB revenue forecast at $74,768,543,403. On average, 10 Wall Street analysts forecast NUVB's revenue for 2027 to be $109,017,603,360, with the lowest NUVB revenue forecast at $62,189,984,746, and the highest NUVB revenue forecast at $140,452,000,831.
In 2028, NUVB is forecast to generate $168,416,923,961 in revenue, with the lowest revenue forecast at $105,174,440,576 and the highest revenue forecast at $247,868,572,059.